Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 25 analyst ratings
Hold
Strong Buy 16%
Buy 20%
Hold 56%
Sell 8%
Strong Sell 0%

Bulls say

Amgen is a leader in biotechnology-based human therapeutics, with a diverse portfolio of flagship drugs that treat a range of diseases and conditions. With a strong track record of success and a rapidly expanding pipeline, the company is well-positioned to continue its growth and transcend potential challenges such as biosimilar competition and tax litigation. Recent data on key products, such as Repatha, have shown strong growth and indicate a promising future for the company, with potential for continued success in both new and established markets.

Bears say

Amgen is facing strong competition in the biotechnology industry, with similar drugs already on the market and newer ones in the pipeline. Additionally, the company's recent acquisition of Onyx Pharmaceuticals and its rare disease drugs may not provide enough growth opportunities to offset potential competition and maintain profitability. The company's biosimilar portfolio may also face challenges in gaining market share. Positive data for its drug Tezspire in EoE is expected, but its potential may be limited compared to its competitor Dupixent. Overall, there are significant risks and uncertainties that may impact Amgen's future financial performance.

Amgen (AMGN) has been analyzed by 25 analysts, with a consensus rating of Hold. 16% of analysts recommend a Strong Buy, 20% recommend Buy, 56% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 25 analysts, Amgen (AMGN) has a Hold consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $394.96, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $394.96, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.